News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
TREU JESSE I
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/11/2020 |
4
| TREU JESSE I (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.|
Txns:
| Granted 26,503 options to buy
@ $5.02, valued at
$133k
Granted 2,465 options to buy
@ $5.02, valued at
$12.4k
Granted 2,311 options to buy
@ $5.02, valued at
$11.6k
|
|
| 08/08/2019 |
4
| DOMAIN PARTERS VII L P (10% Owner) has filed a Form 4 on OBALON THERAPEUTICS INC|
Txns:
| Bought 250,000 shares
@ $4, valued at
$1M
Bought 187,500 options to buy
@ $4.4, valued at
$825k
|
|
| 06/06/2019 |
4
| TREU JESSE I (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.|
Txns:
| Granted 18,951 options to buy
@ $7.06, valued at
$133.8k
Granted 1,763 options to buy
@ $7.06, valued at
$12.4k
Granted 1,653 options to buy
@ $7.06, valued at
$11.7k
|
|
| 05/13/2019 |
3
| DP VIII Associates, L.P. (10% Owner) has filed a Form 3 on Alliqua BioMedical, Inc. |
| 05/13/2019 |
3
| Domain Partners VIII, L.P. (10% Owner) has filed a Form 3 on Alliqua BioMedical, Inc. |
| 03/28/2019 |
4
| TREU JESSE I (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.|
Txns:
| Sold 96,298 shares
@ $10.01, valued at
$963.9k
Sold 445 shares
@ $10.01, valued at
$4.5k
|
|
| 03/04/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/27/2018 |
4
| DOMAIN PARTERS VII L P (10% Owner) has filed a Form 4 on OBALON THERAPEUTICS INC|
Txns:
| Bought 1,648,359 shares
@ $1.82, valued at
$3M
|
|
| 08/27/2018 |
4
| DP VIII Associates, L.P. (10% Owner) has filed a Form 4 on BioNano Genomics, Inc|
Txns:
| Converted 4,386 shares
@ $0
Converted 2,505 shares
@ $4.59, valued at
$11.5k
Converted 50,532 preferred shares
@ $0
Converted 22,161 preferred shares
@ $0
Converted 40,268 preferred shares
@ $0
Converted 47,460 preferred shares
@ $0
Converted 27,328 preferred shares
@ $0
Converted convertible notes
@ $0 |
|
| 08/27/2018 |
4
| Domain Partners VIII, L.P. (10% Owner) has filed a Form 4 on BioNano Genomics, Inc|
Txns:
| Converted 591,184 shares
@ $0
Converted 337,694 shares
@ $4.59, valued at
$1.6M
Bought 15,000 shares
@ $6.125, valued at
$91.9k
Converted 6,810,098 preferred shares
@ $0
Converted 2,986,762 preferred shares
@ $0
Converted 5,426,808 preferred shares
@ $0
Converted 6,396,105 preferred shares
@ $0
Converted 3,682,919 preferred shares
@ $0
Converted convertible notes
@ $0
Bought 15,000 options to buy
@ $6.125, valued at
$91.9k
|
|
| 08/21/2018 |
3
| DP VIII Associates, L.P. (10% Owner) has filed a Form 3 on BioNano Genomics, Inc |
| 08/21/2018 |
3
| Domain Partners VIII, L.P. (10% Owner) has filed a Form 3 on BioNano Genomics, Inc |
| 08/02/2018 |
4
| TREU JESSE I (Director) has filed a Form 4 on VERACYTE, INC.|
Txns:
| Sold 377,188 shares
@ $10.82, valued at
$4.1M
Sold 2,812 shares
@ $10.82, valued at
$30.4k
Sold 119,112 shares
@ $10.85, valued at
$1.3M
Sold 888 shares
@ $10.85, valued at
$9.6k
|
|
| 06/11/2018 |
4
| TREU JESSE I (Director) has filed a Form 4 on Aldeyra Therapeutics, Inc.|
Txns:
| Granted 15,526 options to buy
@ $8.35, valued at
$129.6k
Granted 1,354 options to buy
@ $8.35, valued at
$11.3k
Granted 1,444 options to buy
@ $8.35, valued at
$12.1k
|
|
| 06/08/2018 |
4
| TREU JESSE I (Director) has filed a Form 4 on VERACYTE, INC.|
Txns:
| Granted 10,000 options to buy
@ $7.6, valued at
$76k
|
|
| 12/20/2017 |
4
| DP VIII Associates, L.P. (10% Owner) has filed a Form 4 on Dicerna Pharmaceuticals Inc|
Txns:
| Converted 12,444 shares
@ $3.19, valued at
$39.7k
Granted 282 shares
@ $0
Converted 368 options to buy
@ $3.19, valued at
$1.2k
|
|
| 12/20/2017 |
4
| Domain Partners VIII, L.P. (10% Owner) has filed a Form 4 on Dicerna Pharmaceuticals Inc|
Txns:
| Converted 1,678,432 shares
@ $3.19, valued at
$5.4M
Granted 37,890 shares
@ $0
Converted 49,632 options to buy
@ $3.19, valued at
$158.3k
|
|
| 12/13/2017 |
4
| DOMAIN ASSOCIATES (10% Owner) has filed a Form 4 on Ocera Therapeutics, Inc.|
Txns:
| Disposed/sold 47,963 shares
@ $0 |
|
| 12/13/2017 |
4
| DP VI Associates, L.P. (10% Owner) has filed a Form 4 on Ocera Therapeutics, Inc.|
Txns:
| Disposed/sold 15,731 shares
@ $0 |
|
| 12/13/2017 |
4
| Domain Partners VI, L.P. (10% Owner) has filed a Form 4 on Ocera Therapeutics, Inc.|
Txns:
| Disposed/sold 1,857,036 shares
@ $0
Disposed/sold 20,150 options to buy
@ $0.67, valued at
$13.5k
|
|
| 12/13/2017 |
4
| DP VIII Associates, L.P. (10% Owner) has filed a Form 4 on Ocera Therapeutics, Inc.|
Txns:
| Disposed/sold 7,333 shares
@ $0 |
|
| 12/13/2017 |
4
| Domain Partners VIII, L.P. (10% Owner) has filed a Form 4 on Ocera Therapeutics, Inc.|
Txns:
| Disposed/sold 988,285 shares
@ $0 |
|
| 06/12/2017 |
4
| TREU JESSE I (10% Owner) has filed a Form 4 on Aldeyra Therapeutics, Inc.|
Txns:
| Granted 17,776 options to buy
@ $5.15, valued at
$91.5k
Granted 2,222 options to buy
@ $5.15, valued at
$11.4k
Granted 2,370 options to buy
@ $5.15, valued at
$12.2k
|
|
| 06/09/2017 |
4
| TREU JESSE I (Director) has filed a Form 4 on VERACYTE, INC.|
Txns:
| Granted 10,000 options to buy
@ $7.94, valued at
$79.4k
|
|
| 05/18/2017 |
4
| TREU JESSE I (Director) has filed a Form 4 on VERACYTE, INC.|
Txns:
| Disposed of 25,245 shares
@ $0
Acquired 1,642 shares
@ $0
Acquired 1,641 shares
@ $0
Sold 2,226 shares
@ $8.08, valued at
$18k
|
|
| 04/12/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 04/12/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 11/17/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 11/04/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 11/03/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 11/03/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 11/03/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 11/03/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 10/14/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|
|
|